Al-Maidan Clinic for Oral Health Services Company K.S.C.P. (KWSE:MIDAN)

KWSE:MIDAN Cash Flow Statement

Financials in millions KWD. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	11.82	12.18	10.28	7.81	6.42
Depreciation & Amortization	2.7	2.44	2.35	3.97	3.52
Asset Writedown & Restructuring Costs	-	-0.02	2.16	-	1.22
Loss (Gain) From Sale of Investments	-0.15	0.67	1.37	-0.44	0.54
Loss (Gain) on Equity Investments	0.36	1.07	0.05	-	-
Provision & Write-off of Bad Debts	2.59	2.76	2.61	1.88	1.36
Other Operating Activities	1.52	1.51	-0.31	1.64	0.92
Change in Accounts Receivable	-3.5	-4.8	-1.31	-7.03	-3.07
Change in Inventory	-0.19	-0.03	-0.1	0.6	-1.12
Change in Accounts Payable	-0	2.22	4.62	0.78	1
Change in Other Net Operating Assets	-0.71	-2.83	-0.34	-1.05	-0.23
Operating Cash Flow	14.43	15.17	21.38	8.16	10.57
Operating Cash Flow Growth	-4.87%	-29.07%	162.11%	-22.81%	0.73%
Capital Expenditures	-1.85	-1.55	-1.44	-1.26	-1.37
Investment in Securities	-4.9	1.3	-11	-1.25	-2.44
Investing Cash Flow	-6.75	-0.25	-12.44	-2.51	-3.81
Long-Term Debt Repaid	-0.79	-0.79	-0.81	-0.65	-0.69
Total Debt Repaid	-0.79	-0.79	-0.81	-0.65	-0.69
Net Debt Issued (Repaid)	-0.79	-0.79	-0.81	-0.65	-0.69
Issuance of Common Stock	-	0.01	-	-	-
Repurchase of Common Stock	-2.25	-2.5	-	-	-
Common Dividends Paid	-1.12	-0	-2.49	-1.75	-1.74
Other Financing Activities	-0.04	0.01	-	-	-
Financing Cash Flow	-4.2	-3.27	-3.29	-2.4	-2.43
Net Cash Flow	3.48	11.64	5.65	3.25	4.33
Free Cash Flow	12.57	13.62	19.94	6.9	9.19
Free Cash Flow Growth	-7.64%	-31.72%	189.08%	-24.97%	-0.60%
Free Cash Flow Margin	16.60%	18.75%	28.16%	11.32%	16.64%
Free Cash Flow Per Share	0.06	0.06	0.09	0.03	0.04
Cash Interest Paid	0.08	0.01	-	-	-
Levered Free Cash Flow	6.2	7.5	14.01	4.41	4.05
Unlevered Free Cash Flow	6.31	7.56	14.07	4.49	4.13
Change in Net Working Capital	0.66	1.39	-4.91	2.51	1.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.